BRIEF-Stoke Therapeutics Expects To Complete Enrollment Of 150 Patients In Q2 2026, With A Phase 3 Data Readout In Mid-2027 for Zorevunersen

Reuters01-12

BRIEF-Stoke <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Expects To Complete Enrollment Of 150 Patients In <a href="https://laohu8.com/S/QTWO">Q2</a> 2026, With A Phase 3 Data Readout In Mid-2027 for Zorevunersen

Jan 11 (Reuters) - Stoke Therapeutics Inc STOK.O:

STOKE THERAPEUTICS ANNOUNCES UPDATES TO TIMELINES FOR THE COMPLETION OF ENROLLMENT AND A PHASE 3 DATA READOUT FROM THE EMPEROR STUDY OF ZOREVUNERSEN FOR THE TREATMENT OF DRAVET SYNDROME
STOKE THERAPEUTICS INC: EXPECTS TO COMPLETE ENROLLMENT OF 150 PATIENTS IN Q2 2026, WITH A PHASE 3 DATA READOUT IN MID-2027
STOKE THERAPEUTICS INC - CONTINUES TO EXPLORE POTENTIAL FOR EXPEDITED DEVELOPMENT, REGISTRATION AND DELIVERY OF ZOREVUNERSEN TO PATIENTS

Source text: ID:nBw1dlkjsa

Further company coverage: STOK.O

((Reuters.briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602557734?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 03:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602557734","market":"nz","top_or_hot":-1,"title":"BRIEF-Stoke Therapeutics Expects To Complete Enrollment Of 150 Patients In Q2 2026, With A Phase 3 Data Readout In Mid-2027 for Zorevunersen","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Stoke <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Expects To Complete Enrollment Of 150 Patients In <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, With A Phase 3 Data Readout In Mid-2027 for Zorevunersen</title></head><body><p><span>Jan 11 (Reuters)</span><span> - </span>Stoke Therapeutics Inc <span>STOK.O</span>:</p><ul><li><p>STOKE THERAPEUTICS ANNOUNCES UPDATES TO TIMELINES FOR THE COMPLETION OF ENROLLMENT AND A PHASE 3 DATA READOUT FROM THE EMPEROR STUDY OF ZOREVUNERSEN FOR THE TREATMENT OF DRAVET SYNDROME</p></li><li><p>STOKE THERAPEUTICS INC: EXPECTS TO COMPLETE ENROLLMENT OF 150 PATIENTS IN Q2 2026, WITH A PHASE 3 DATA READOUT IN MID-2027</p></li><li><p>STOKE THERAPEUTICS INC - CONTINUES TO EXPLORE POTENTIAL FOR EXPEDITED DEVELOPMENT, REGISTRATION AND DELIVERY OF ZOREVUNERSEN TO PATIENTS</p></li></ul><p>Source text: <span>ID:nBw1dlkjsa</span></p><p>Further company coverage: <span>STOK.O</span></p><p> ((Reuters.briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Stoke Therapeutics Expects To Complete Enrollment Of 150 Patients In Q2 2026, With A Phase 3 Data Readout In Mid-2027 for Zorevunersen</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Stoke Therapeutics Expects To Complete Enrollment Of 150 Patients In Q2 2026, With A Phase 3 Data Readout In Mid-2027 for Zorevunersen\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 03:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Stoke <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Expects To Complete Enrollment Of 150 Patients In <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, With A Phase 3 Data Readout In Mid-2027 for Zorevunersen</title></head><body><p><span>Jan 11 (Reuters)</span><span> - </span>Stoke Therapeutics Inc <span>STOK.O</span>:</p><ul><li><p>STOKE THERAPEUTICS ANNOUNCES UPDATES TO TIMELINES FOR THE COMPLETION OF ENROLLMENT AND A PHASE 3 DATA READOUT FROM THE EMPEROR STUDY OF ZOREVUNERSEN FOR THE TREATMENT OF DRAVET SYNDROME</p></li><li><p>STOKE THERAPEUTICS INC: EXPECTS TO COMPLETE ENROLLMENT OF 150 PATIENTS IN Q2 2026, WITH A PHASE 3 DATA READOUT IN MID-2027</p></li><li><p>STOKE THERAPEUTICS INC - CONTINUES TO EXPLORE POTENTIAL FOR EXPEDITED DEVELOPMENT, REGISTRATION AND DELIVERY OF ZOREVUNERSEN TO PATIENTS</p></li></ul><p>Source text: <span>ID:nBw1dlkjsa</span></p><p>Further company coverage: <span>STOK.O</span></p><p> ((Reuters.briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STOK","symbol_name":"Stoke Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA8ZB7PR:1","article_id":"2602557734","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602557734","pubTimestamp":1768158189,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Stoke Therapeutics Expects To Complete Enrollment Of 150 Patients In Q2 2026, With A Phase 3 Data Readout In Mid-2027 for ZorevunersenJan 11 (Reuters) - Stoke Therapeutics Inc STOK.O:STOKE THERA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"STOK":"Stoke Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"BRIEF-Stoke Therapeutics预计将在2026年第二季度完成150名患者的入组，并于2027年中期读取Zorevunersen的3期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STOK":0.9},"content_text":"BRIEF-Stoke Therapeutics Expects To Complete Enrollment Of 150 Patients In Q2 2026, With A Phase 3 Data Readout In Mid-2027 for ZorevunersenJan 11 (Reuters) - Stoke Therapeutics Inc STOK.O:STOKE THERAPEUTICS ANNOUNCES UPDATES TO TIMELINES FOR THE COMPLETION OF ENROLLMENT AND A PHASE 3 DATA READOUT FROM THE EMPEROR STUDY OF ZOREVUNERSEN FOR THE TREATMENT OF DRAVET SYNDROMESTOKE THERAPEUTICS INC: EXPECTS TO COMPLETE ENROLLMENT OF 150 PATIENTS IN Q2 2026, WITH A PHASE 3 DATA READOUT IN MID-2027STOKE THERAPEUTICS INC - CONTINUES TO EXPLORE POTENTIAL FOR EXPEDITED DEVELOPMENT, REGISTRATION AND DELIVERY OF ZOREVUNERSEN TO PATIENTSSource text: ID:nBw1dlkjsaFurther company coverage: STOK.O ((Reuters.briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602557734","isCrawlerRequest":true}